Strata Critical Medical（SRTA）株式概要
ストラタ・クリティカル・メディカル社は、米国の医療業界にタイムクリティカルなロジスティクスと医療サービスを提供している。 詳細
SRTA Community Fair Values
Create NarrativeSee what 26 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Strata Critical Medical, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$5.09 |
| 52週高値 | US$6.50 |
| 52週安値 | US$3.68 |
| ベータ | 2.22 |
| 1ヶ月の変化 | -3.51% |
| 3ヶ月変化 | 0.098% |
| 1年変化 | 27.44% |
| 3年間の変化 | 29.22% |
| 5年間の変化 | -29.38% |
| IPOからの変化 | -47.85% |
最新ニュース
Seeking Alpha • Jul 07
Strata Critical Medical: A Better Alternative To TransMedics In Organ Transplant Logistics
Summary Strata Critical Medical is rated a buy, driven by expanding market share, operational efficiencies, and a comprehensive suite of transplant logistics and clinical services. SRTA's asset-light-to-moderate model, strategic acquisitions, and focus on NRP technology position it to benefit from industry consolidation and secular tailwinds. Gross margin improvement is a key near-term catalyst, with management incentivized to reach 25% margins by 2027; Q1 2026 gross margin reached 21%. TransMedics faces slowing growth, margin compression, and competitive headwinds, leading to a hold rating as TMDX's market share and valuation multiples are expected to converge with SRTA. Read the full article on Seeking Alpha
ナラティブ更新 • Jun 22
SRTA: Index Inclusion And 2026 Guidance Reaffirmation Will Support Future Upside
Analysts have raised their price target on Strata Critical Medical by $0.25, citing updated assumptions that include slightly higher projected revenue growth, stronger profit margins, and a lower future P/E multiple, which together support a modestly higher valuation. Analyst Commentary Recent Street research around Strata Critical Medical highlights a mix of optimism about the company’s potential and a more cautious tone around how much of that potential is already reflected in the valuation.
ナラティブ更新 • Jun 07
SRTA: Fresh Bullish Coverage And 2026 Guidance Will Support Future Upside
Narrative Update: Strata Critical Medical The analyst price target for Strata Critical Medical has moved from $11.25 to $11.50. Analysts point to fresh bullish coverage and updated assumptions on revenue growth, profit margins and future P/E multiples as key drivers of the change.Recent updates
Seeking Alpha • Jul 07
Strata Critical Medical: A Better Alternative To TransMedics In Organ Transplant Logistics
Summary Strata Critical Medical is rated a buy, driven by expanding market share, operational efficiencies, and a comprehensive suite of transplant logistics and clinical services. SRTA's asset-light-to-moderate model, strategic acquisitions, and focus on NRP technology position it to benefit from industry consolidation and secular tailwinds. Gross margin improvement is a key near-term catalyst, with management incentivized to reach 25% margins by 2027; Q1 2026 gross margin reached 21%. TransMedics faces slowing growth, margin compression, and competitive headwinds, leading to a hold rating as TMDX's market share and valuation multiples are expected to converge with SRTA. Read the full article on Seeking Alphaナラティブ更新 • Jun 22
SRTA: Index Inclusion And 2026 Guidance Reaffirmation Will Support Future Upside
Analysts have raised their price target on Strata Critical Medical by $0.25, citing updated assumptions that include slightly higher projected revenue growth, stronger profit margins, and a lower future P/E multiple, which together support a modestly higher valuation. Analyst Commentary Recent Street research around Strata Critical Medical highlights a mix of optimism about the company’s potential and a more cautious tone around how much of that potential is already reflected in the valuation.ナラティブ更新 • Jun 07
SRTA: Fresh Bullish Coverage And 2026 Guidance Will Support Future Upside
Narrative Update: Strata Critical Medical The analyst price target for Strata Critical Medical has moved from $11.25 to $11.50. Analysts point to fresh bullish coverage and updated assumptions on revenue growth, profit margins and future P/E multiples as key drivers of the change.
ナラティブ更新 • May 24
SRTA: Bullish Coverage And 2026 Revenue Guidance May Support Future Upside
Strata Critical Medical's updated analyst price target has moved to $9.13 from $8.81, as analysts point to revised assumptions around growth, margins, and future P/E expectations following recent bullish coverage and a $0.25 increase in one firm's target. Analyst Commentary Recent Street research on Strata Critical Medical has leaned positive, with several firms initiating bullish coverage and one lifting its price target by $0.25.分析記事 • May 08
Strata Critical Medical, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Investors in Strata Critical Medical, Inc. ( NASDAQ:SRTA ) had a good week, as its shares rose 6.4% to close at US$5.34...ナラティブ更新 • May 08
SRTA: Higher 2026 Guidance And Mixed Risk Signals Will Support Future Upside
Analysts have nudged their average price target for Strata Critical Medical higher by $0.25, reflecting a slightly stronger profit outlook and updated P/E assumptions. At the same time, they have tempered revenue growth expectations and applied a modestly higher discount rate.ナラティブ更新 • Apr 20
SRTA: Bullish Execution On Raised 2026 Revenue Outlook May Unlock Future Upside
The Analyst Price Target for Strata Critical Medical has been revised from $9.63 to $8.81, with analysts pointing to updated assumptions on revenue growth, profit margins, and a higher forward P/E multiple, despite generally bullish recent coverage. Analyst Commentary Recent research coverage on Strata Critical Medical has been largely constructive, with analysts updating their models to reflect revised assumptions on revenue, margins, and valuation multiples.ナラティブ更新 • Apr 06
SRTA: Raised Revenue Outlook And Richer Future P/E Will Support Upside
Analysts have raised their price target on Strata Critical Medical to $8.00 per share, citing updated assumptions around revenue growth, profit margins, and a higher future P/E multiple, supported by recent bullish initiation reports from multiple firms. Analyst Commentary Recent bullish initiation reports on Strata Critical Medical highlight constructive views on the company’s long term prospects, but not all commentary is aligned with that optimism.ナラティブ更新 • Mar 23
SRTA: Higher Revenue Outlook And Richer Future P/E Will Drive Upside
Analysts have revised their price target on Strata Critical Medical to $8.00. This reflects updated assumptions for significantly higher revenue growth, lower profit margins, and a substantially higher future P/E multiple.ナラティブ更新 • Mar 09
SRTA: Higher Revenue Outlook And Impairment Charge Will Support Future Upside
Analysts have adjusted their price target on Strata Critical Medical to $9.63, reflecting updated assumptions that combine a different discount rate and future P/E with materially higher modeled revenue growth and slightly lower profit margins. What's in the News Strata Critical Medical raised its 2026 revenue guidance to a range of $260 million to $275 million, compared with the prior range of $255 million to $270 million (Key Developments).ナラティブ更新 • Feb 22
SRTA: Higher Margin Outlook Will Support Future Earnings Power
Analysts have adjusted their price target on Strata Critical Medical to $8.00, reflecting updated assumptions for slightly higher revenue, improved profit margins, a modestly higher discount rate, and a lower future P/E multiple. Valuation Changes Fair Value: $8.00 stays unchanged, with the revised assumptions still pointing to the same central estimate.ナラティブ更新 • Feb 07
SRTA: Higher Margins And Updated Guidance Will Support Stronger Future Returns
Analysts have modestly reset their price target for Strata Critical Medical to $11.25, citing updated assumptions around slightly higher revenue growth, tighter profit margins at 18.60% and a lower future P/E of about 25.74x as key drivers of the revised view. What's in the News Strata Critical Medical issued earnings guidance for 2026, expecting revenue between $255 million and $270 million.ナラティブ更新 • Jan 24
SRTA: Higher Margin Outlook And Revenue Guidance Will Support Earnings Power
Analysts have adjusted their price target on Strata Critical Medical to $8.00. The updated view reflects slightly different assumptions around revenue growth, profit margin and future P/E that they see as better aligning with their current outlook for the business.ナラティブ更新 • Jan 09
SRTA: Higher Margin Outlook Will Drive Stronger Earnings Power Ahead
Analysts have raised their fair value estimate for Strata Critical Medical from $5.00 to $8.00, citing updated assumptions that include a lower discount rate, a revised outlook for revenue growth, higher expected profit margins, and a reduced future P/E multiple. What's in the News Strata Critical Medical issued earnings guidance for 2026, with expected revenue in a range of $255 million to $270 million.分析記事 • Jan 06
Strata Critical Medical, Inc.'s (NASDAQ:SRTA) 30% Price Boost Is Out Of Tune With Revenues
Strata Critical Medical, Inc. ( NASDAQ:SRTA ) shares have had a really impressive month, gaining 30% after a shaky...ナラティブ更新 • Dec 17
SRTA: Lower Risk Profile And Rising Margins Will Drive Stronger Future Returns
Analysts have raised their price target for Strata Critical Medical from 6.50 dollars to 11.25 dollars, citing a lower perceived risk profile and materially stronger long term profitability expectations, despite moderating revenue growth assumptions and a slightly lower future P E multiple. What's in the News Strata Critical Medical issued 2026 revenue guidance, forecasting between 255 million dollars and 270 million dollars.ナラティブ更新 • Dec 03
SRTA: Keystone Acquisition Will Drive Expanded Cash Deployment And Future Earnings Upside
Analysts have nudged their price target on Strata Critical Medical higher to $9.63 from $9.25, citing the strategically accretive Keystone Perfusion Services acquisition and the company’s more constructive growth outlook as key drivers. Analyst Commentary Bullish analysts view the Keystone Perfusion Services acquisition as a strategically important use of Strata Critical Medical's sizable cash balance.ナラティブ更新 • Nov 19
SRTA: Keystone Acquisition Will Drive Material Revenue Expansion And Lower Risk
Analysts have raised their price target for Strata Critical Medical to $7.25, up from $6.50. They cite strong support for the company's recent acquisition of Keystone Perfusion Services as a strategic use of its significant cash reserves.ナラティブ更新 • Nov 03
SRTA: Cash Deployment Through Acquisition Will Drive Expansion In Healthcare Reach
Analysts have raised their price target for Strata Critical Medical to $9.25, up from $7.83. They cited stronger strategic deployment of cash resources with the acquisition of Keystone Perfusion Services and improved expectations for future performance.ナラティブ更新 • Sep 23
Critical Organ Transport And Joby Aviation Will Expand Healthcare Reach
Strata Critical Medical’s consensus price target has risen from $5.83 to $7.83, as analysts express increased confidence in management’s ability to deploy capital efficiently and drive shareholder value following the accretive acquisition of Keystone Perfusion Services. Analyst Commentary Bullish analysts highlight the successful deployment of Strata's large $235M pro forma cash position through the acquisition of Keystone Perfusion Services for $124M.ナラティブ更新 • Aug 06
Critical Organ Transport And Joby Aviation Will Expand Healthcare Reach
The consensus analyst price target for Blade Air Mobility has increased, primarily driven by higher revenue growth forecasts and a rising future P/E, bringing the fair value estimate up from $7.20 to $7.75. What's in the News Joby Aviation is exploring an acquisition of Blade Air Mobility to access a ready customer base for electric air taxis; no final decision has been made.分析記事 • May 15
Earnings Release: Here's Why Analysts Cut Their Blade Air Mobility, Inc. (NASDAQ:BLDE) Price Target To US$7.20
Blade Air Mobility, Inc. ( NASDAQ:BLDE ) investors will be delighted, with the company turning in some strong numbers...分析記事 • May 13
Blade Air Mobility, Inc. (NASDAQ:BLDE) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected
Those holding Blade Air Mobility, Inc. ( NASDAQ:BLDE ) shares would be relieved that the share price has rebounded 29...
新しいナラティブ • Mar 31
eVTOL And Urban Air Mobility Will Open New Routes
Transition to electric vertical aircraft (eVTOL) promises long-term growth by enabling new routes and attracting a wider customer base.Seeking Alpha • Feb 26
Blade Air Mobility: Organ Transport Growth Now, eVTOL Growth Later
Summary Blade currently focuses on organ transport and passenger transport. The company is expanding in the organ logistics market. New perfusion technologies and competition provide a risk to the business. Air taxi services using eVTOLs provide a margin expansion opportunity. The stock is a speculative buy at this point. Read the full article on Seeking Alpha分析記事 • Nov 30
Revenues Not Telling The Story For Blade Air Mobility, Inc. (NASDAQ:BLDE) After Shares Rise 27%
Despite an already strong run, Blade Air Mobility, Inc. ( NASDAQ:BLDE ) shares have been powering on, with a gain of...Seeking Alpha • Nov 18
Blade: Transition To Profitability Should Provide Support Going Forward
Summary Blade's growth was weak in Q3, largely due to the company abandoning activities with marginal economics. Policy reforms and new technologies are driving growth in transplant volumes and transportation distances but competition is likely to increase in coming quarters. Provided Blade's margins continue to improve, the stock should move higher at some point. This will likely require an improvement in growth though. eVTOLs should provide Blade's passenger segment with a significant boost but this remains several years away. Read the full article on Seeking Alpha分析記事 • Nov 15
Analysts Have Made A Financial Statement On Blade Air Mobility, Inc.'s (NASDAQ:BLDE) Third-Quarter Report
Last week, you might have seen that Blade Air Mobility, Inc. ( NASDAQ:BLDE ) released its third-quarter result to the...分析記事 • Sep 16
Blade Air Mobility, Inc.'s (NASDAQ:BLDE) Business Is Trailing The Industry But Its Shares Aren't
When you see that almost half of the companies in the Airlines industry in the United States have price-to-sales ratios...Seeking Alpha • Aug 15
Blade: Margins Remain An Issue
Summary Blade Air Mobility, Inc.'s business continues to expand, but revenue growth is being dampened by the company's decision to discontinue unprofitable activities. Competition from TransMedics poses a threat, and this issue is likely to come to a head in coming quarters. While Blade has managed to reduce its losses, stock-based compensation is causing fairly significant dilution. Blade's low valuation could be an opportunity, but the company probably needs to stabilize its growth and address dilution before the stock moves higher. Read the full article on Seeking Alpha分析記事 • Jun 19
Here's Why We're Not At All Concerned With Blade Air Mobility's (NASDAQ:BLDE) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Seeking Alpha • May 16
Blade Air Mobility: No Signs Of Competition Yet
Summary Rising organ transportation competition poses a threat to Blade's Medical segment, but Q1 revenue suggests there hasn't been a material impact so far. TransMedics' strong logistics growth and aggressive expansion plan put Blade and TransMedics on a collision course in coming years. Blade's valuation is low though, and if the Medical segment continues to grow or eVTOLs expand the UAM market, the stock could perform well. Read the full article on Seeking Alpha分析記事 • May 10
Analysts Are Updating Their Blade Air Mobility, Inc. (NASDAQ:BLDE) Estimates After Its First-Quarter Results
Blade Air Mobility, Inc. ( NASDAQ:BLDE ) defied analyst predictions to release its first-quarter results, which were...株主還元
| SRTA | US Healthcare | US 市場 | |
|---|---|---|---|
| 7D | -0.1% | -0.4% | -2.6% |
| 1Y | 27.4% | 39.8% | 14.3% |
業界別リターン: SRTA過去 1 年間で39.8 % の収益を上げたUS Healthcare業界を下回りました。
リターン対市場: SRTA過去 1 年間で14.3 % の収益を上げたUS市場を上回りました。
価格変動
| SRTA volatility | |
|---|---|
| SRTA Average Weekly Movement | 7.3% |
| Healthcare Industry Average Movement | 7.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: SRTA 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: SRTAの 週次ボラティリティ ( 7% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2014 | 327 | Melissa Tomkiel | www.stratacritical.com |
米国の医療業界にタイムクリティカルなロジスティクスと医療サービスを提供。ロジスティクスとクリニカルの2つのセグメントで事業を展開している。同社は、臓器、移植チーム、関連医療材料の空輸や地上輸送、臓器配置サービスなどのロジスティクス・サービスと、臓器回復手順、正常温存局所灌流、保存サービスなどの移植臨床サービスを提供している。また、心臓灌流サービス、血液管理・自己血輸血サービス、体外膜酸素化サービス、灌流スタッフ派遣、機器レンタルなどの臨床サービスも提供している。同社は以前はブレード・エア・モビリティ社として知られていたが、2025年8月にストラタ・クリティカル・メディカル社に社名を変更した。同社は2014年に設立され、ニューヨーク州ニューヨークに本社を置いている。
Strata Critical Medical, Inc. 基礎のまとめ
| SRTA 基礎統計学 | |
|---|---|
| 時価総額 | US$421.38m |
| 収益（TTM） | -US$16.05m |
| 売上高(TTM) | US$228.58m |
1.9x
P/Sレシオ-27.4x
PER（株価収益率SRTA は割高か？
公正価値と評価分析を参照収益と収入
| SRTA 損益計算書（TTM） | |
|---|---|
| 収益 | US$228.58m |
| 売上原価 | US$180.39m |
| 売上総利益 | US$48.19m |
| その他の費用 | US$64.24m |
| 収益 | -US$16.05m |
直近の収益報告
Mar 31, 2026
次回決算日
Aug 04, 2026
| 一株当たり利益（EPS） | -0.19 |
| グロス・マージン | 21.08% |
| 純利益率 | -7.02% |
| 有利子負債／自己資本比率 | 0% |
SRTA の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/30 00:48 |
| 終値 | 2026/07/30 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Strata Critical Medical, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6
| アナリスト | 機関 |
|---|---|
| Yuan Zhi | B. Riley Securities, Inc. |
| Itay Michaeli | Citigroup Inc |
| William Bonello | Craig-Hallum Capital Group LLC |